Tenon(R) Medical Reports Third Quarter 2026 Financial Results
Key Highlights
- ➤Q3 revenue $1.4 million, up 22% year over year
- ➤Q3 operating loss $3.1 million, improving $0.3 million year over year
- ➤Cash $8.3 million; raised $15.6 million and ended quarter debt-free
- ➤3D-printed SImmetry+ lateral screw commercially launched after $1.2 million alpha-launch revenue
- ➤Quickstep Decorticator full market release targeted for Q1 2027
Expert Statements
Steven M. Foster, President and CEO of Tenon Medical, Inc.
“Third quarter revenue of $1.4 million grew 22% compared to the prior year and 12% sequentially from the second quarter, and we delivered that growth while reducing operating expenses compared to both the third quarter of 2025 and the second quarter of this year.”
Steven M. Foster, President and CEO of Tenon Medical, Inc.
“Just as importantly, we significantly strengthened our balance sheet during the quarter. We raised approximately $15.6 million in aggregate gross proceeds, repaid our convertible notes in full, regained compliance with Nasdaq's stockholders' equity and minimum bid price requirements, and ended the quarter with $8.3 million in cash.”
Steven M. Foster, President and CEO of Tenon Medical, Inc.
“With our convertible notes now behind us, our attention is fully on growth. The full commercial launch of our 3D-printed SImmetry+ lateral screw, the first component of our next-generation lateral system, and the completion of initial alpha cases with our Quickstep™ Decorticator, which we are targeting for full market release in the first quarter of 2027, expand the tools we can offer our physician partners.”
Steven M. Foster, President and CEO of Tenon Medical, Inc.
“Our eight new U.S. patents this year further strengthen the protection around our Catamaran® platform.”
Steven M. Foster, President and CEO of Tenon Medical, Inc.
“For the balance of 2026, our priorities remain consistent: expanding physician training and adoption across both platforms, advancing our product pipeline, and maintaining discipline on spend.”
LOS GATOS, CA / ACCESS Newswire / November 12, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon Medical" or the "Company"), a company redefining care for patients with sacro-pelvic disorders, today reported financial results for the third quarter ended September 30, 2026.
Financial Results and Business Updates * Third Quarter 2026 Results:* Third quarter revenue of $1.4 million, an increase of 22% compared to $1.2 million in the third quarter of 2025. * Third quarter gross profit of $1.0 million, an increase of 23% compared to $0.8 million in the third quarter of 2025. * Gross margin of 66.3%, a 0.4 percentage point increase from 65.9% in the third quarter of 2025. * Cash and cash equivalents of $8.3 million as of September 30, 2026, compared to $3.8 million as of December 31, 2025. * Operating loss of $3.1 million in the third quarter, an improvement of $0.3 million compared to $3.4 million in the third quarter of 2025. * Net loss of $6.6 million, or $5.39 per share, in the third quarter of 2026, compared to a net loss of $3.3 million, or $14.17 per share, in the third quarter of 2025.
Get started
Create a free account to read the full story.